About Francesco

Francesco Negro is Professor at the Departments of Specialty Medicine and of Pathology and Immunology of the University of Geneva, Switzerland. He is also Founder and Chairman of the Swiss Hepatitis C Cohort Study, and Educational Councilor of the European Association for the Study of the Liver.

Professor Negro earned his medical degree in 1982 and was board-certified in Gastroenterology in 1986 at the University of Torino, Italy. He undertook post-doctoral training at the Division of Molecular Virology and Immunology, Georgetown University, USA, and at the Hepatitis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA, between 1986 and 1989. Professor Negro analysed hepatitis C virus (HCV) replication at the tissue level using several distinct approaches, establishing anatomo-clinical correlations. His studies led him to associate HCV genotype 3a with a particular form of severe liver steatosis, and to analyse the mechanisms thereof.

More recently, Professor Negro’s work has focused on the pathogenesis of extrahepatic manifestations associated with HCV, and, particularly, on the mechanisms leading to glucose metabolism alterations, such as insulin resistance and diabetes, and on the epidemiology of HCV. He has participated in several clinical trials in acute and chronic HCV and has authored or co-authored more than 270 peer-reviewed manuscripts in the field of hepatology.

This speaker will be presenting at the following session(s)

  • Liver societies' role towards viral hepatitis elimination

    Matisse

    Day: 2 November

    Time: 08:00

    Topics to be discussed:

    • Prevention of mother to child transmission of HBV and strategies to increase HBV vaccine coverage (in particular birth dose coverage) and antiviral therapy for highly viremic HBsAg+ mothers.
    • Improving diagnosis of persons chronically infected with HBV or HCV.
    • Improving linkage to care of persons diagnosed to have chronic HBV or HCV, in particular vulnerable populations and persons living in rural areas.
    • Improving access to antiviral treatment of persons with chronic HBV or HCV.